NT-proBNP rules out heart failure cost-effectively
This article was originally published in Clinica
Executive Summary
Measuring blood levels of the cardiac peptide NT-proBNP in general practice provides a useful means of ruling out heart failure, and reduces diagnostic expenditure by Euro21 ($26) per patient, a Danish study has shown.